Search the GHTC website

Global health R&D delivers for Ohio

US government investment in global health R&D has delivered

$599.1 million
to Ohio research institutions
8,100+ new jobs
for Ohio
Ohio's top USG-funded global health R&D institutions

Ohio's top USG-funded global health R&D institutions

Case Western Reserve University (including Cleveland Clinic Lerner College of Medicine)
$213.7 million
Ohio State University
$100.2 million
Cincinnati Children's Hospital Medical Center
$52.8 million
Clinical Research Management Inc. (clinicalRM)*
$25.7 million
University of Cincinnati
$13.5 million
University of Toledo
$12.1 million
Cleveland State University
$8.2 million
Nationwide Children's Hospital
$7.3 million
Meridian Bioscience
$5.9 million
Guild Associates Inc.
$5.2 million
Ohio University
$2.4 million
University Hospitals Cleveland
$1.9 million
Wright State University
$1.2 million
Flow Pharma Inc.
$767 thousand
Northeast Ohio Medical University
$541 thousand
The College of Wooster
$371 thousand
Guild BioSciences
$370 thousand
MetalloPharm LLC*
$278 thousand
Diascopic LLC
$258 thousand
METSS Corporation
$99 thousand
Akron Rubber Development Lab Inc.
$95 thousand

Ohio's top areas of global health R&D by USG funding

Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Snakbite envenoming
Reproductive health
Salmonella infections
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Cryptococcal meningitis
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Hepatitis C
Multi-disease/health area R&D
Rheumatic fever
Global health R&D at work in Ohio

Cincinnati Children’s Hospital Medical Center led early-stage clinical trials of two Shigella vaccine candidates. Worldwide, Shigella causes more than 150 million cases of severe diarrhea and dysentery annually, including 450,000 cases in the United States, and kills an estimated 600,000 people each year, most of whom are young children in low-income countries. Antibiotics are the standard treatment, but drug-resistant strains are spreading at an alarming rate, and no vaccine is yet available—underscoring the importance of continued vaccine development efforts.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Patrick McKern